Back to PharmaIndex

Pancicare-D Capsule PR

Domperidone (30mg) + Pantoprazole (40mg)

Drug details

API

Domperidone (30mg) + Pantoprazole (40mg)

Drug classification

Prokinetic and proton pump inhibitor; specifically, dopamine antagonist and substituted benzimidazole PPI.

Dosage form

Prolonged-release oral capsule containing domperidone and pantoprazole.

API strength per dosage

Dose

Standard adult dosing for Pancicare-D Capsule PR (Domperidone 30 mg + Pantoprazole 40 mg) is typically once daily before meals. Use in children is not routinely recommended. Domperidone is contraindicated in moderate to severe hepatic impairment and should be used with caution in renal impairment; dose adjustments may be necessary. Always follow local prescribing guidelines.

Mechanism of action

Pantoprazole inhibits the H+/K+ ATPase (proton pump) in gastric parietal cells, reducing gastric acid secretion. Domperidone is a dopamine D2 receptor antagonist in the chemoreceptor trigger zone and gastrointestinal tract, enhancing gastrointestinal motility and accelerating gastric emptying while reducing nausea and vomiting.

Indications

Treatment of Gastroesophageal reflux disease (Acid reflux)Treatment of Peptic ulcer disease

Side effects

Diarrhea Stomach pain Flatulence Dryness in mouth Dizziness Headache

Pregnancy category

Domperidone and pantoprazole should be used in pregnancy only if clearly needed; safety data in pregnant women are limited, so consult a healthcare provider.

Precautions

Contraindicated in gastrointestinal bleeding or obstruction, prolactin-secreting tumor, caution in hepatic impairment, risk of QT prolongation, monitor for cardiac arrhythmias, electrolyte disturbances, CNS side effects, monitor magnesium with long-term use, assess for symptom improvement, avoid in pregnancy and lactation unless clearly needed.

Contraindications

Hypersensitivity to domperidone, pantoprazole, or excipients, prolactin-releasing pituitary tumor (prolactinoma), gastrointestinal bleeding or obstruction, perforation, moderate or severe hepatic impairment, concomitant QT-prolonging drugs, known QT prolongation, cardiac arrhythmias.

PharmaProLearn

Excel Beyond Limits